Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. Its natural history is defined by progression restricted to the peritoneal space. In the past, patients with this disease had a limited lifespan of approximately 1 year. Numerous single-institution studies as well as a systematic review have reported median survival of 3 to 5 years with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy. These markedly improved survival statistics were achieved in experienced centers with 1% mortality and 20% morbidity rates. Data have shown that knowledgeable patient selection is required to prevent patients unlikely to benefit from undergoing these interventions. The conclusion is that patients with peritoneal mesothelioma can experience long-term progression-free survival or significant palliation with cytoreductive surgery plus hyperthermic perioperative chemotherapy. This management plan should be considered the standard of care for properly selected patients with malignant peritoneal mesothelioma at experienced centers around the world.
INTRODUCTION
There are approximately 800 new cases of malignant peritoneal mesothelioma diagnosed annually in the United States, with equal incidence of the disease in male and female patients. 1 Moertel, 2 in his review, attributes the earliest collection of 12 documented cases of peritoneal mesothelioma to Winslow and Taylor. 3 Management remained palliative until Antman et al 4 suggested chemotherapy treatment alternatives in their management of six patients with malignant peritoneal mesothelioma. Brenner et al 5 defined the natural history of the disease in 25 patients as continuously localized to the peritoneal space or progressing by direct extension through the diaphragm to the pleural space. Real progress in management emerged several decades later, when a new combined surgical and regional chemotherapy treatment strategy emerged. 6, 7 The first multi-institutional consensus meeting was hosted by the National Cancer Institute in Bethesda, Maryland, in September 2004, proceedings of which were published in 2006. 8 A second international consensus statement came from the Peritoneal Surface Oncology Group Biennial Meeting in Milan, Italy, in 2006. 9 On the basis of data currently available, combined treatment with cytoreductive surgery (CRS) followed in the operating room by hyperthermic perioperative chemotherapy (HIPEC) has become the standard of care in selected patients where the expertise of experienced caregivers is available. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] A multiinstitutional registry evaluated CRS combined with HIPEC for malignant peritoneal mesothelioma in 2009. These authors from 10 different institutions concluded that CRS combined with HIPEC achieved prolonged survival in selected patients with this disease. 23 A meta-analysis concluded that CRS plus HIPEC has led to improved survival for patients with malignant peritoneal mesothelioma. 24 Unfortunately, substantial improvements in survival with the use of systemic chemotherapy as treatment have not been forthcoming. [25] [26] [27] There have been responses showing potential palliative benefit, but survival has not been prolonged. 28 Although experienced treatment centers are able to provide optimal care for some patients with malignant peritoneal mesothelioma in the United States and Europe, a majority of patients around theworldreceive only palliativecare or systemic chemotherapy with cisplatin and pemetrexed or cisplatin and gemcitabine. In a review of treatment in the United States of 1,591patientswith malignant peritoneal mesothelioma between 1973 and 2010, Miura et al 29 concluded that approximately three of every five patients did not receive surgery when diagnosed with malignant peritoneal mesothelioma. This failure to treat persisted despite the significant survival benefit noted in select patients. The opportunity to improve patient survival with surgical therapy was lost in a significant number of patients with malignant peritoneal mesothelioma. The purpose of this report is to summarize recommendations for intervention with CRS accompanied by HIPEC as the first line of treatment whenever possible. This combined treatment has the potential for cure, has acceptable morbidity and mortality risks, and should become available around the globe for selected patients. A challenge is to provide knowledgeable and technically proficient management worldwide.
ESTABLISHING DIAGNOSIS AND SELECTION OF PATIENTS FOR CRS AND HIPEC
The most common symptoms of peritoneal mesothelioma are pain (dry type) and/or ascites (wet type). Patients often require a biopsy, usually using computed tomography (CT) guidance or laparoscopy through the linea alba. 15 Peritoneal cytology of ascites does not usually establish a definitive diagnosis. Pathology must be reviewed. A core or tissue biopsy is preferred. In most cases, histopathology of the tumor shows epithelioid features, although it is difficult to predict biologic behavior (aggressive v indolent) based on histopathology alone. Sarcomatoid or biphasic histologic types are usually excluded from CRS and HIPEC (Fig 1) . CT of chest, abdomen, and pelvis or CT of chest plus magnetic resonance imaging of abdomen and pelvis is obtained. An experienced radiologist must communicate the presence or lack of so-called concerning radiologic features. This radiologic interpretation should contribute to the judgments regarding probability of complete cytoreduction versus debulking surgery (Fig 2) . 30, 31 Although no formal consensus regarding criteria for patient selection for potentially curative treatment exists, Table 1 lists favorable and guarded clinical features. Although the selection of patients occurs based on host and disease factors, the extent of disease also influences the ability to cytoreduce and the degree of cytoreduction. This important assessment is best estimated using an intraoperative quantitation of all sites of disease within the abdomen and pelvis, known as the peritoneal cancer index. The distribution and extent of disease at 13 specific sites are recorded as part of the patient's permanent record. 32 The safety and feasibility of laparoscopy have been demonstrated in patients with peritoneal surface malignancies by several groups. 33, 34 Although laparoscopy may lead to understaging of the disease burden, it is a useful technique to determine if some patients have extensive burden of disease, which may preclude the benefit of cytoreduction. Laparoscopy port site recurrence is a consideration that must be noted in placement of ports.
CRS
If a patient does not have coexisting medical conditions that would result in high surgical risk and if complete cytoreduction or significant debulking is predicted, CRS can be recommended. Surgery must be performed by an experienced surgical team, with the understanding that complete cytoreduction may require up to six peritonectomy procedures and multiple visceral resections. 7 The surgical team must have experience in making the necessary intraoperative judgments regarding the different surgical maneuvers that may be needed and must be proficient with these procedures. Although the extent of peritonectomy is limited at most institutions to peritoneal surfaces visibly infiltrated by disease (selective peritonectomy), other groups have recommended total parietal peritonectomy (systematic peritonectomy). 34 Presence of lymph node metastases has been shown to be a factor associated with shortened survival, and lymph node metastases are included in a proposed staging system for patients with peritoneal mesothelioma. 35 During the CRS procedure, assessment of the lymph nodes in the regions that are explored surgically is routinely performed by some but not all centers. All enlarged lymph nodes should be removed and submitted for permanent histologic section. Node sampling is also recommended. The exact anatomic sites to be used for lymphadenectomy have not been clearly defined. Lymph node groups that have been recommended for histopathologic assessment to rule out the presence of involved abdominal or pelvic lymph nodes include the deep epigastric lymph nodes, external iliac lymph nodes at the internal inguinal ring, common iliac lymph nodes, lymph nodes at the origin of the gastroepiploic vessels, or accessible lymph nodes present in the mediastinum immediately above the superior surface of the diaphragm.
35,36
Although there is complete agreement regarding the importance of complete or near-complete cytoreduction in the surgical management of malignant peritoneal mesothelioma, some controversy does exist regarding the use of selective versus complete parietal peritonectomy. Baratti et al 37 reported a 5-year survival rate with selective peritonectomy of 40%, as compared with a survival rate of 63.9% with complete parietal peritonectomy (P 5 .0269). They performed this complete parietal peritonectomy without increased morbidity or mortality. Peritoneal mesothelioma has a pattern of intraperitoneal dissemination considerably different from that of other malignancies with metastases to peritoneal surfaces. The redistribution characteristic of mucinous appendiceal tumor with relative sparing of small bowel and its mesentery is rarely Algorithm for management of patients with malignant peritoneal mesothelioma. CRS, cytoreductive surgery; CT, computed tomography; EPIC, early postoperative intraperitoneal chemotherapy; HIPEC, hyperthermic perioperative chemotherapy; MRI, magnetic resonance imaging; PET, positron emission tomography. *Consider second-look laparoscopy in 6 months to 1 year. †No adjuvant chemotherapy regimen has been studied extensively. Maintenance intraperitoneal pemetrexed plus intravenous cisplatin may be considered after CRS plus HIPEC. ‡HIPEC for palliation of ascites, which can be performed laparoscopically, may be considered.
observed. 38 Parietal peritoneal surfaces are typically diffusely involved, and extensive peritonectomy is usually required. The perihepatic regions may present a considerable challenge, especially the posterior aspect of the hepatoduodenal ligament. A unique finding is extensive involvement of small-and large-bowel mesenteries, with sparing of the surface of the bowel. In some patients, to achieve a complete cytoreduction, an attempt to remove the visceral peritoneum on the smallbowel mesentery must be made. 39 This may require a combination of small-and large-bowel resections, especially of splenic flexure and rectosigmoid colon.
HIPEC
Immediately after CRS and before intestinal reconstruction and abdominal closure, the abdomen and pelvis must be prepared for HIPEC. Hemostasis must be complete, or bleeding during HIPEC will be wasteful. Irrigation is indicated to mechanically clear loose cancer cells from all peritoneal surfaces. Extensive intraoperative peritoneal lavage has been used with good results in gastric cancer. 40 Some have recommended copious distilled water, whereas other groups have used diluted (0.25%) hydrogen peroxide or povidone iodine. 41, 42 After mechanical cleansing of the peritoneal space by irrigation, all patients who undergo complete or near-complete cytoreduction should be treated with HIPEC. Standard recommendations include the use of a platinum-based agent such as cisplatin if renal function is adequate. 24 Different chemotherapeutic options have been explored, including high-dose cisplatin (250 mg/m 2 ), cisplatin plus doxorubicin, cisplatin plus mitomycin, and mitomycin alone ( Table 2) . One option is to use bidirectional chemotherapy by adding systemic ifosfamide plus mesna disulfide by continuous infusion for the 90 minutes of HIPEC with doxorubicin and cisplatin. Two retrospective studies have shown an association with better survival using cisplatin compared with mitomycin. 22, 24 In the absence of data derived from prospectively conducted clinical trials, an HIPEC regimen familiar to the caregivers must be considered an institutional standard of care for patients with peritoneal mesothelioma. An additional treatment currently routinely used at some institutions is early postoperative intraperitoneal chemotherapy with paclitaxel. 43 Long-term intraperitoneal chemotherapy through an intraperitoneal port combined with systemic chemotherapy has also been reported to be of benefit (Sugarbaker et al, manuscript submitted for publication). These bidirectional intraperitoneal/systemic chemotherapy regimens are similar to those successfully used for ovarian cancer. 44 There is a new concept regarding the use of HIPEC in peritoneal mesothelioma after acceptable (CC-0/CC-1/CC-2) cytoreduction. HIPEC is a necessary part of the management plan but is not sufficient in some patients who are at high risk of early recurrence. The role of other locoregional chemotherapy treatment strategies is being evaluated in clinical studies. In some patients, clinical and radiologic evaluation indicates a small likelihood of complete or near-complete cytoreduction. 
CONTRAST OF CRS FOR MALIGNANT PERITONEAL MESOTHELIOMA VERSUS GI CANCER
There are differences in the rationale for CRS plus HIPEC in patients with malignant peritoneal mesothelioma as compared with patients with peritoneal metastases from GI cancer. Data would suggest that patients with significant debulking yet incomplete cytoreduction significantly benefit from the use of HIPEC. In other words, if CRS can be used to separate all of the bowel loops and reduce the size of the nodules to 1 cm or smaller, HIPEC is considered to be of benefit and, in some instances, is associated with long-term progression-free survival. Sugarbaker et al 15 found a clear difference in patient survival when CC-0 to CC-2 cytoreductions were compared with CC-3 cytoreductions. However, no statistically significant difference was seen when CC-0 and CC-1 cytoreductions were compared with CC-2 cytoreductions. Accepting the fact that CC-0 to CC-1 cytoreduction is always the goal, this strategy of more complete cytoreduction, better survival, is a rationale in ovarian cancer as well as in malignant peritoneal mesothelioma. 29 There is a clear contrast in the survival of patients who undergo complete versus incomplete cytoreduction for high-grade GI cancer. As reported by Goere et al, 48 in performing abdominal exploration for a GI malignancy with peritoneal metastases, if complete cytoreduction is judged to be impossible, the procedure is either aborted or palliative intervention becomes the goal of surgery.
MORBIDITY AND MORTALITY OF CRS AND HIPEC
For CRS and HIPEC to be regarded as standard of care in selected patients, the morbidity and mortality risks must be acceptable. This combined treatment involves a long surgical procedure (up to 12 hours) with intraperitoneal chemotherapy. There is potential for intraoperative and/or postoperative complications, even postoperative death. Although experienced centers have reported an acceptable incidence of mortality and morbidity, a steep learning curve for this combined treatment exists and presents a major challenge in educational efforts at university centers. Although data were not specific for peritoneal mesothelioma, Kusamura et al 49 showed that transition from suboptimal performance to technologic and oncologic success required a median of 100 procedures. Outcomes at centers early in their experience may be considerably less optimal than those at experienced centers. To qualify as an experienced center with more than 50 patients per year, not all patient cases must involve malignant peritoneal mesothelioma. However, this diagnosis includes patients who will require a team with maximal knowledge and technical expertise for an optimal outcome.
In 
